Clinical Trial Gurus

JULY 2, 2021

Oncology is arguably the most complex sector in all of clinical research. In this interview, an experienced clinical research coordinator discusses why this is the case.

Clinical Research Coordinator 52

Clinical Research Coordinator Clinical Research Research 52

Clinical Trial Gurus

OCTOBER 16, 2021

Oncology clinical research is probably one of the most challenging specializations. In this video I interview an oncologist who discusses what in particular may make oncology a challenge for a clinical research newbie.

Clinical Research 52

Clinical Research Research 52

Pharmaceutical Technology

AUGUST 8, 2022

Time to progression in pain, castration-resistant prostate cancer, first symptomatic skeletal event, the commencement of successive anticancer treatment, all analysed at 12?week week intervals, as well as adverse events (AEs) as a measure of safety and tolerability were the trial’s secondary endpoints.

Hormones 246

Hormones Clinical Trials Clinical Trials Licensing 246

XTalks

DECEMBER 4, 2023

Most oncology products approved in the past few decades are known for being highly toxic, non-specific and fraught with severe side effects for cancer patients. But today, with a rise in molecularly targeted therapies, oncology development has shifted to identifying an optimal biologic dose that balances toxicity with efficacy.

Development 111

Development Drugs Clinical Trials Clinical Trials 111

Drug Discovery World

NOVEMBER 14, 2023

The event, which will be sponsored by Taconic Biosciences, will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and will also be available on-demand. Register for free to secure your place and to receive your exclusive download link after the event.

Research 52

Research Genome Genomics Antibody 52

Drug Discovery World

JUNE 15, 2023

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, which took place in April 2023, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research, who you will hear from across three episodes of the DDW Events Podcast series.

Research 52

Research Drugs 52

STAT News

DECEMBER 7, 2022

“I think we need to actually start policing ourselves better,” Brawley, a professor of oncology and epidemiology at John Hopkins University and former chief medical officer and executive vice president at the American Cancer Society, said at a STAT virtual event on Tuesday. Read the rest…

Medicine 105

Medicine Doctors Doctor 105

Pharmaceutical Technology

SEPTEMBER 5, 2022

Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years. “We In this period, AstraZeneca has also taken part in five oncology and respiratory disease deals, respectively. billion in development.

FDA Approval 287

FDA Approval Clinical Trials Clinical Trials Development 287

Drug Discovery World

NOVEMBER 2, 2023

The event will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and will also be available on-demand. Register for free to secure your place and to receive your exclusive download link after the event. Register for free to secure your place and to receive your exclusive download link after the event.

Research 52

Research Genome Genomics Medicine 52

Drug Channels

NOVEMBER 14, 2023

It’s time for our most popular event of the year! Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. Dr. Adam J. to 1:30 p.m.

Drugs 77

Drugs Pharmacy Marketing 77

Drug Discovery World

OCTOBER 26, 2023

The event will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and will also be available on-demand. Register for free to secure your place and to receive your exclusive download link after the event. Why therapeutic cancer vaccines are the next frontier in immuno-oncology.

Research 52

Research Antibody Vaccination Vaccine 52

Worldwide Clinical Trials

OCTOBER 17, 2022

Phase 3 oncology studies have approximately a 35% likelihood of leading to regulatory approval. There are particular challenges for oncology studies, in view of the fact that the overall likelihood of non-oncology Phase 3 studies leading to approval averages 65%. Even with optimized enrollment, adverse events occur.

Trials 100

Trials Clinical Trials Clinical Trials Drugs 100

Pharmaceutical Technology

JUNE 4, 2023

At the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting, being held 2–6 June, new data was presented from the randomized, controlled Phase III KEYNOTE-671 study of MSD’s Keytruda (pembrolizumab) (abstract LBA100). months, the two-year event-free survival (EFS) was 62.4% At a median duration of follow-up of 25.2

HR 189

HR FDA Approval Trials Marketing 189

Clinical Trial Gurus

AUGUST 18, 2021

Oncology clinical research is a world of its own. Full of challenges, different medical terminology, graded adverse events and so much more. In this video I speak with a clinical research coordinator who shares her own experiences in the world of oncology clinical trials.

Clinical Research Coordinator 52

Clinical Research Coordinator Clinical Research Research Clinical Trials 52

Pharmaceutical Technology

APRIL 4, 2023

Dr Robert Casero and Dr Tracy Murray Stewart, both belonging to the oncology section of the Johns Hopkins University School of Medicine, will lead the research. The partners will also focus on the further evaluation of ivospemin’s mechanism of action, as well as its potential combination with CPP-1X and standard of care agents.

Development 147

Development Clinical Trials Clinical Trials Medicine 147

Drug Discovery World

FEBRUARY 29, 2024

CureLab Oncology’s DNA vaccine Elenagen, in combination with chemotherapy, has demonstrated promising clinical results against triple-negative ovarian cancer. There were no serious adverse events (SAEs) reported in patients receiving Elenagen. Gemcitabine alone had an average PFS similar to previously reported durations: 2.7

DNA 52

DNA Drugs Vaccination Vaccine 52

Drug Discovery World

OCTOBER 31, 2023

Raffi Tonikian DDW is delighted to confirm that the event will feature a talk by Dr Raffi Tonikian, Director of Translational Biomarkers at AbCellera, sharing his broad expertise in autoimmunity and oncology. The post DDW Cancer Summit: Master biomarker-driven approaches appeared first on Drug Discovery World (DDW).

In-Vitro 52

In-Vitro Research Medicine Development 52

pharmaphorum

AUGUST 24, 2020

Could collecting, understanding, and disseminating patient-reported outcomes during trials be the key to advancing oncology treatments and improving cancer outcomes? . Project Patient Voice is a dedicated online platform that makes patient-reported symptoms and adverse events (AEs) from the trial data of marketed drugs publicly available.

Trials 128

Trials Clinical Trials Clinical Trials Production 128

VirTrial

FEBRUARY 28, 2024

If you missed Signant’s February 2024 webinar about optimizing patient-reported outcomes measurement strategy throughout oncology drug development, we’ve summarized the key takeaways and provided a link for you to watch the recording. Most said, “some of the time,” followed by “never.”

Development 52

Development Drugs Trials Clinical Development 52

BioTech 365

JANUARY 4, 2021

Polyphor AG / Key word(s): Conference 05-Jan-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Allschwil, Switzerland, January 5, 2021 Polyphor to take … Continue reading →

40

40

BioTech 365

JUNE 7, 2021

MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of … Continue reading → DGAP-News: MagForce AG / Key word(s): Miscellaneous 07.06.2021 / 08:30 The issuer is solely responsible for the content of this announcement.

40

40

XTalks

DECEMBER 29, 2023

XTALKS WEBINAR: Strategic Implications of Oncology Clinical Trial Design in Early-Phase Studies Live and On-Demand: Friday, February 16, 2024, at 11am EST (4pm GMT/UK) Register for this free webinar to delve into how strategic oncology clinical trial design shapes success in early oncology studies using novel approaches.

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

Drug Discovery World

FEBRUARY 16, 2024

DDW recently hosted an online event, sponsored by Taconic Biosciences, which outlined areas of advancement and opportunity in the cancer research market. New drug discovery and development concepts The event started with a panel discussion on new drug discovery and development concepts and tools in cancer research.

Research 52

Research In-Vitro Drugs Vaccination 52

pharmaphorum

SEPTEMBER 30, 2022

Genetic testing has become vastly more accessible in the last 20 years and has opened all kinds of doors in medicine, from pharmacogenetics and better understanding drug interactions and adverse events to tremendous advances in oncology: understanding the underlying genetics of cancer cells has allowed delivery of affective, targeted treatments.

Behavioural Health 98

Behavioural Health Genetics Medicine Drugs 98

Pharmaceutical Technology

JANUARY 2, 2023

According to GlobalData, the latest event to affect Lifirafenib maleate’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway. BeiGene overview BeiGene is a biotechnology company.

Drugs 100

Drugs Development Clinical Trials Clinical Trials 100

XTalks

JULY 21, 2023

These members now have access to the advanced Iris platform, offering specialized mental health care tailored for oncology patients, 24×7 symptom management and essential nutritional support. All of these services are available at no cost through participating health plans.

Nurses 98

Nurses Doctors Doctor Clinical Trials 98

pharmaphorum

NOVEMBER 15, 2021

Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.

Clinical Trials 52

Clinical Trials Clinical Trials Genetics Medicine 52

BioTech 365

JULY 7, 2021

Crescendo to Participate in Upcoming Investor Events Crescendo to Participate in Upcoming Investor Events CAMBRIDGE, England–(BUSINESS WIRE)–Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that senior members of the executive … (..)

Development 52

Development 52

Drug Discovery World

JANUARY 10, 2023

The Opening Plenary on Sunday, April 16 will be chaired by Programme Chair Robert H Vonderheide and will feature talks by leading researchers on topics including real-world data and precision oncology, immune response in the tumour microenvironment, equity in cancer care, viral-induced malignancies, and cancer cachexia. .

Immune Response 52

Immune Response Clinical Trials Clinical Trials Research 52

pharmaphorum

APRIL 6, 2021

With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. Taking place as a fully interactive digital event, this is y our chance to hear the latest advances and innovations in the preclinical cell therapy space. There is a crucial need to progress candidates from bench to bedside.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

Drug Discovery World

MARCH 14, 2023

Life sciences membership organisation OBN (UK) will be holding in-person event BioTrinity 2023 in London on April 25-26. The conference will feature two tracks: ‘Scientific’, showcasing innovation across eight core therapy areas, and ‘Life Sciences Business & Investment’.

Life Science 52

Life Science Gene Therapy Gene Drugs 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). Grade 3 or greater treatment-related adverse events (TRAEs) occurred in 31% of patients receiving doublet therapy and 58% of patients receiving triplet therapy.

Trials 40

Trials Antibody Development Genome 40

pharmaphorum

NOVEMBER 17, 2020

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications. Take a look at the full program here.

Development 52

Development Drugs Clinical Development 52

Drug Discovery World

DECEMBER 1, 2022

Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies), lack of an optimal biomarker is one of the main challenges to clinical trial success. Director, Application Development, LevitasBio will present the event. Camila Egidio. Register here.

RNA 52

RNA Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JULY 3, 2023

From June 20-22, 2023, Cambridge Healthtech Institute hosted the seventh annual Immuno-Oncology Summit Europe in London. The post Immuno-Oncology Summit Europe 2023: Programme highlights appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

BioTech 365

NOVEMBER 11, 2020

Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20 Ascendis Pharma A/S to Host Virtual Oncology R&D Day on Friday, November 20 – Event will provide an overview of how Ascendis is applying its TransCon™ technology … Continue reading →

40

40

Drug Discovery World

FEBRUARY 14, 2024

There will also be a trade show and exhibition, a poster competition, and networking opportunities.

Research 52

Research Medicine Drugs Scientist 52